Inhaled Insulin

Source: www.moreover.com --- 41 days ago
Genetic Engineering News Oct 8 2008 8:50PM GMT ...

Source: news.google.com --- 63 days ago
MannKind's Inhaled Insulin meets study goal CNNMoney.com - 1 hour ago NEW YORK (Associated Press) - Biotechnology company MannKind Corp. said Tuesday its Inhaled Insulin system met the main goal of regulating blood-sugar in a late-stage study focusing on Type 1 diabetes patients. UPDATE 1-Mannkind Inhaled Insulin meets study goal Reuters MannKind and Pfizer Announce Collaboration for Certain Exubera ... MarketWatch Wall Street Journal  - Forbes  - RTT News  - Earthtimes (press release) all 23 news articles ...

Source: www.ncbi.nlm.nih.gov --- 130 days ago
Related Articles Inhaled Insulin for the early detection of lung cancer. Med Hypotheses. 2008 Jul 2; Authors: Lehrer S PMID: 18602221 [PubMed - as supplied by publisher] ...

Source: www.ncbi.nlm.nih.gov --- 93 days ago
Related Articles Inhaled Insulin: a novel and non-invasive way for Insulin administration? Curr Drug Saf. 2006 May;1(2):151-8 Authors: Quattrin T Over the past few years significant steps forward have been made towards the development of Insulin formulations suitable for inhalation via several delivery systems. This innovative route of Insulin delivery offers the potential of administering pre-meal Insulin in a non-invasive way to patients currently receiving multiple daily injections. This article describes the pharmacodynamic and pharmacokinetic profiles and the efficacy and safety data of Inhaled Insulin preparations. Particular emphasis is placed on Exubera, which currently has the largest pool of efficacy and safety data. In patients with type 1 diabetes 24-week trials have demonstrated that Inhaled Insulin was equally efficacious to short acting Insulin (2-4 daily injections). Results of trials conducted in type 2 diabetes showed Inhaled Insulin efficacy too, and a potential role for Inhaled Insulin in patients failing oral medications. Safety data have shown that the most common reported adverse event is mild cough, which appears to be decreasing in frequency during the course of therapy. Higher antibody titers have been observed in patients treated with Inhaled Insulin compared to subjects treated with sub-cutaneous Insulin. However, the titers do not present any association with clinical correlates. The safety area in need of ...

Source: www.ncbi.nlm.nih.gov --- 13 days ago
Related Articles Pure Insulin Nanoparticle Agglomerates for Pulmonary Delivery. Langmuir. 2008 Oct 30; Authors: Bailey MM, Gorman EM, Munson EJ, Berkland C Diabetes is a set of diseases characterized by defects in Insulin utilization, either through autoimmune destruction of Insulin-producing cells (Type I) or Insulin resistance (Type II). Treatment options can include regular injections of Insulin, which can be painful and inconvenient, often leading to low patient compliance. To overcome this problem, novel formulations of Insulin are being investigated, such as Inhaled aerosols. Sufficient deposition of powder in the peripheral lung to maximize systemic absorption requires precise control over particle size and density, with particles between 1 and 5 mum in aerodynamic diameter being within the respirable range. Insulin nanoparticles were produced by titrating Insulin dissolved at low pH up to the pI of the native protein, and were then further processed into microparticles using solvent displacement. Particle size, crystallinity, dissolution properties, structural stability, and bulk powder density were characterized. We have demonstrated that pure drug Insulin microparticles can be produced from nanosuspensions with minimal processing steps without excipients, and with suitable properties for deposition in the peripheral lung. PMID: 18959432 [PubMed - as supplied by publisher] ...

Source: www.ncbi.nlm.nih.gov --- 104 days ago
Related Articles Efficacy and Safety of Technosphere Inhaled Insulin Compared With Technosphere Powder Placebo in Insulin-Naive Type 2 Diabetes Suboptimally Controlled with Oral Agents. Diabetes Care. 2008 Aug 4; Authors: Rosenstock J, Bergenstal R, Defronzo RA, Hirsch IB, Klonoff D, Boss A, Kramer D, Petrucci R, Yu W, Levy B, Objective- This double-blind, placebo-controlled, randomized, multicenter, parallel-group study compared the efficacy, safety, and tolerability of Technosphere(R) Insulin (TI) with Technosphere(R) powder (TP) as placebo in Insulin-naïve type 2 diabetic patients suboptimally controlled with oral antidiabetic agents. Research design and methods- Patients (n=126) were randomized to 12 weeks of therapy with TI or TP following lifestyle education on nutrition, exercise, and instructions on inhaler use. The primary efficacy outcome was change in glycosylated hemoglobin A1C (A1C) from baseline to study end, and the secondary efficacy outcome was area under the curve for postprandial glucose levels during a meal test at treatment weeks 4, 8, and 12. Results- A1C reduction from a mean baseline of 7.9% was greater with TI than with TP (-0.72% vs. -0.30%; P=0.003). Postprandial glucose excursions were reduced by 56% with TI compared with baseline, and maximal postprandial glucose levels were reduced by 43% compared with TP. Incidences of hypoglycemia, hyperglycemia, cough, and other adverse events were low in both groups. B ...

Source: www.marketwatch.com --- 28 days ago
Pfizer said early Tuesday that its third-quarter profit more than tripled year-over-year, due largely to steep charges taken during last year’s period for the discontinuation of its Inhaled Insulin product Exubera. ...

Source: blogs.wsj.com --- 8 days ago
Pfizer is looking for buyer for the manufacturing plant for the now-defunct Inhaled Insulin called Exubera. ...

Source: blogs.wsj.com --- 63 days ago
The last major player developing an Inhaled form of Insulin says results from a late-stage study look promising, but there's a long way to go. ...

Source: www.marketwatch.com --- 62 days ago
BOSTON (MarketWatch) -- Drug stocks were mixed in early trading Tuesday, the day after the Dow Jones Industrial Average dove almost 500 points on renewed concerns about the health of the U.S. banking industry. The Amex Pharmaceutical Index declined 0.7% to 296.0 while the Amex Biotechnology Index inched up marginally to 792.3. Mannkind Corp. was a notable mover amongst the biotech small caps, with shares tumbling 1% to $3.00. Mannkind announced early Tuesday that Pfizer Inc. plans to switch some remaining users of Pfizer's discontinued Inhaled Insulin product Exubera to similar product being developed by Mannkind called Technosphere. Mannkind also reported positive preliminary data from a Phase III study of Technosphere in the treatment of type 1 diabetes. ...

Source: www.latimes.com --- 63 days ago
Company releases test results showing that its Technosphere Insulin delivery system is as effective for diabetics as injections. But investors are still wary about safety, and Mannkind's stock slumps. Even after biotechnology company MannKind Corp. released new data on its experimental Insulin inhaler today, the Valencia-based company has been unable to assuage the safety concerns that decimated its stock in April. ...

Source: www.latimes.com --- 62 days ago
The company releases test results showing that its Technosphere Insulin delivery system is as effective for diabetics as injections. But investors are still wary about safety; MannKind's stock slumps. Valencia biotechnology company MannKind Corp. thought it had encouraging news about its experimental Insulin inhaler on Tuesday. But Wall Street wasn't buying it. ...

Source: www.medscape.com --- 80 days ago
In a 2-year safety study, Inhaled human Insulin treatment caused small changes in forced expiratory volume in 1 second in patients with type 2 diabetes. Medscape Medical News ...

Source: industry.bnet.com --- 60 days ago
After burning $2.8 billion, Pfizer is throwing yet more money on the Inhaled Insulin bonfire. The company’s announcement that it has a deal to switch former Exubera patients to MannKind’s TechnoSphere is a real head-scratcher. One unanswered question is, exactly how many Exubera patients are there? Pfizer recorded Exubera’s revenue in the third quarter of 2007 [...] ...

Source: diabetes.taragana.net --- 62 days ago
MannKind Corporation, a biopharmaceutical company, announces the results of the experiments of their Inhaled Insulin product. The company has done an year long experiment. Finally they have come to the conclusion that the product is effective in controlling the blood-glucose levels and didn’t raise concerns about lung function. MannKind said the results are from one [...] ...

Source: www.fiercebiotech.com --- 63 days ago
Mannkind took another big step toward filing an application for its Inhaled Insulin after releasing data from a late-stage trial demonstrating the therapy is not inferior to injected drugs that control blood sugar levels in Type 1 diabetes patients. Just as importantly, researchers noted that there was no difference in lung function measures for patients taking Mannkind's therapy, a safety factor that has dogged similar therapies. Mannkind has stuck with its Inhaled Insulin program even after Pfizer, Eli Lilly and Novo Nordisk had all walked away from their own efforts in the field. In a separate announcement Pfizer said that some Exubera patients who still need an Inhaled Insulin will be switched to Mannkind's therapy. Investors have battered the company's stock price, but the CEO says Mannkind plans to go the distance. "Technosphere Insulin promises to be an important additional option for the treatment of patients with Type 1 diabetes," MannKind Chief Scientific Officer Peter Richardson said in a statement. An application should follow in the next few months. - check out the Mannkind release - read the story from the Wall Street Journal Related Articles: Pfizer kills off Exubera, hunts for deals Inhaled Insulin lung cancer warning riles investors Novo Nordisk shelves Inhaled Insulin, axes staffers Alkermes: Lilly may dump Inhaled Insulin program MannKind bets the farm on Inhaled Insulin  (Nov 2007) ...

Source: www.fiercepharma.com --- 7 days ago
Call your Realtor: Pfizer has put its ex-Exubera plant up for sale. The Terre Haute, Indiana, facility had been in the Pfizer family since 1948, when the drugmaker bought it from the U.S. government. Since then, it's undergone a variety of expansions and upgrades, including more than $300 million in investment since 1999. At its peak, the 580,000-square-foot facility on almost 1,000 acres employed some 800 people. Most recently, the plant was used to make Exubera, Pfizer's Inhaled Insulin product. But just one year into the product's launch, Pfizer pulled the plug on the formulation because of lackluster sales. Exubera just hadn't caught on with patients, who disliked the oversized inhaler device. And payers were slow to adopt the Inhaled formula, too. Pfizer took a $2.8 billion charge to shut down production; about 600 Terre Haute workers were idled at the time. - read the story in the Indianapolis Star - see the Wall Street Journal Health Blog post Related Articles: Pfizer gives Nektar $135M for Exubera settlement  (Nov 2007) Pfizer kills off Exubera, hunts for deals (Oct 2007) Exubera becoming a big disappointment for Pfizer (Apr 2007) UK: Exubera not worth the price  (Apr 2006) FDA approves Pfizer's Inhaled Insulin  (Jan 2006) ...

Source: www.devicelink.com --- 64 days ago
Alfred Mann does, and he’s betting nearly $1 billion that his Inhaled Insulin–Technosphere–will be cleared for sale in the United States. Embarking on an area of the market that proved unsuccessful for Eli Lilly, Pfizer, and Novo Nordisk, Mann’s company, MannKind Corp., will be releasing data from clinical trials involving Technosphere tomorrow, Bloomberg.com reports. [...] ...